Product Images Fesoterodine Fumarate

The text describes a figure labeled as "Figure 1" that shows a change in the number of micturitions (urinations) per 24 hours over the course of 12 weeks in a study. The figure displays results for a placebo group, a group taking Fosoterodine fumarate at a dose of 4mg, and a group taking Fesoterodine fumarate at a dose of 8mg. The text contains no further information about the study or its findings.*

This text describes a figure that illustrates the change in urge incontinence episodes over a 12-week period in Study 1. The chart compares the results of a placebo group (consisting of 211 participants) with the results of two different drug treatments, Fosotorosine fumarate 4mg (N=198) and Fesolerodine fumarate 8mg (N=223). The figure shows the mean change from the baseline at weeks 2, 8, and 12.*

This text presents the mean change from the baseline in terms of the number of micturitions per 24 hours in a study involving three groups: a placebo group with 266 participants, a group using fesoterodine fumarate 4mg with 267 participants, and a group using fesoterodine fumarate 8mg with 267 participants. The data is represented in Figure 3, which shows the change in the number of micturitions per 24 hours over time in weeks.*

This is a figure depicting the change in urge incontinence episodes per 24 hours for three groups of participants (placebo, fesolorodine fumarate 4mg, and fesoterodine fumarate 8mg) over the course of several weeks. The graph shows that the two medication groups experienced a decrease in episodes compared to the placebo group. Mean change from baseline is not specified.*

This is a package of Fesoterodine, which is an extended-release tablet used to treat the symptoms of an overactive bladder such as urinary incontinence and urgency. The package contains 30 tablets and should be taken whole without chewing. The manufacturer is Vilacto Bio Inc. with an address in India. No dosage or prescription information is provided.*